表紙
市場調查報告書

消化器官疾病治療藥的全球市場:2020年∼2024年

Global Gastrointestinal Diseases Therapeutics Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 934845
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
消化器官疾病治療藥的全球市場:2020年∼2024年 Global Gastrointestinal Diseases Therapeutics Market 2020-2024
出版日期: 2020年04月28日內容資訊: 英文 120 Pages
簡介

全球消化器官疾病治療藥市場在2020年∼2024年的預測期間內,預計將以9%的年複合成長率增長,預計達到228億2,000萬美元萬美元的規模。市場成長的主要因素有消化系統疾病的發病率增加,新藥上市以及對生物製劑和靶向療法的需求。

本報告提供全球消化器官疾病治療市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各類藥物市場區隔

  • 市場區隔
  • 各類藥物比較:市場規模·預測(2019年∼2024年)
  • 抗發炎劑和免疫抑制劑
  • 酸中和劑
  • 其他的治療藥物
  • 各類藥物市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模·預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 各地區市場機會
  • 交易量的成長要素-需求主導型成長
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 業者情勢
  • 形勢的創新
  • 產業風險

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA

附錄

目錄
Product Code: IRTNTR43343

Technavio has been monitoring the gastrointestinal diseases therapeutics market and it is poised to grow by $ 22.82 bn during 2020-2024 progressing at a CAGR of 9% during the forecast period. Our reports on gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of gastrointestinal diseases, new product launches, and demand for biologics and targeted therapies. In addition, increasing incidence of gastrointestinal diseases is anticipated to boost the growth of the market as well.

The gastrointestinal diseases therapeutics market analysis includes drug class segment and geographic landscapes

Technavio's ‘ gastrointestinal diseases therapeutics market ’ is segmented as below:

By Drug Class

  • Anti-inflammatory and immunosuppressors
  • Acid neutralizers
  • Other therapeutics

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the strong product pipeline as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years. Also, funding for gastrointestinal research studies, and increase in self-medication coupled with home-based therapies will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our gastrointestinal diseases therapeutics market covers the following areas:

  • Gastrointestinal diseases therapeutics market sizing
  • Gastrointestinal diseases therapeutics market forecast
  • Gastrointestinal diseases therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastrointestinal diseases therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA. Also, the gastrointestinal diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Drug class

  • Market segments
  • Comparison by Drug class
  • Anti-inflammatory and immunosuppressors - Market size and forecast 2019-2024
  • Acid neutralizers - Market size and forecast 2019-2024
  • Other therapeutics - Market size and forecast 2019-2024
  • Market opportunity by Drug class

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver - Demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption
  • Industry risks

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ billion)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: Anti-inflammatory and immunosuppressors - Market size and forecast 2019-2024 ($ billion)
  • 24: Anti-inflammatory and immunosuppressors - Year-over-year growth 2019-2024 (%)
  • 25: Acid neutralizers - Market size and forecast 2019-2024 ($ billion)
  • 26: Acid neutralizers - Year-over-year growth 2019-2024 (%)
  • 27: Other therapeutics - Market size and forecast 2019-2024 ($ billion)
  • 28: Other therapeutics - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Other1
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ billion)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ billion)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ billion)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ billion)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ billion)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Abbott Laboratories - Overview
  • 50: Abbott Laboratories - Business segments
  • 51: Abbott Laboratories - Key offerings
  • 52: Abbott Laboratories - Key customers
  • 53: Abbott Laboratories - Segment focus
  • 54: AbbVie Inc. - Overview
  • 55: AbbVie Inc. - Business segments
  • 56: AbbVie Inc. - Key offerings
  • 57: AbbVie Inc. - Key customers
  • 58: AbbVie Inc. - Segment focus
  • 59: AstraZeneca Plc - Overview
  • 60: AstraZeneca Plc - Business segments
  • 61: AstraZeneca Plc - Key offerings
  • 62: AstraZeneca Plc - Key customers
  • 63: AstraZeneca Plc - Segment focus
  • 64: Bausch Health Companies Inc. - Overview
  • 65: Bausch Health Companies Inc. - Business segments
  • 66: Bausch Health Companies Inc. - Key offerings
  • 67: Bausch Health Companies Inc. - Key customers
  • 68: Bausch Health Companies Inc. - Segment focus
  • 69: Boehringer Ingelheim International GmbH - Overview
  • 70: Boehringer Ingelheim International GmbH - Business segments
  • 71: Boehringer Ingelheim International GmbH - Key offerings
  • 72: Boehringer Ingelheim International GmbH - Key customers
  • 73: Boehringer Ingelheim International GmbH - Segment focus
  • 74: GlaxoSmithKline Plc - Overview
  • 75: GlaxoSmithKline Plc - Business segments
  • 76: GlaxoSmithKline Plc - Key offerings
  • 77: GlaxoSmithKline Plc - Key customers
  • 78: GlaxoSmithKline Plc - Segment focus
  • 79: Johnson & Johnson - Overview
  • 80: Johnson & Johnson - Business segments
  • 81: Johnson & Johnson - Key offerings
  • 82: Johnson & Johnson - Key customers
  • 83: Johnson & Johnson - Segment focus
  • 84: Merck & Co. Inc. - Overview
  • 85: Merck & Co. Inc. - Business segments
  • 86: Merck & Co. Inc. - Key offerings
  • 87: Merck & Co. Inc. - Key customers
  • 88: Merck & Co. Inc. - Segment focus
  • 89: Takeda Pharmaceutical Co. Ltd. - Overview
  • 90: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 91: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 92: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 93: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 94: UCB SA - Overview
  • 95: UCB SA - Business segments
  • 96: UCB SA - Key offerings
  • 97: UCB SA - Key customers
  • 98: UCB SA - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations